Reverse Phase Protein Microarray Technology: Advances into the Clinical Research Arena

Emanuel F. Petricoin; Brian Leyland-Jones; Julie Wulfkuhle; Marielena Pierobon; Claudius Mueller; Virginia Espina; Lance A. Liotta

doi:10.1016/B978-0-12-394446-7.00022-4

Reverse Phase Protein Microarray Technology: Advances into the Clinical Research Arena

Emanuel F. Petricoin^*, Brian Leyland-Jones, Julie Wulfkuhle, Marielena Pierobon, Claudius Mueller, Virginia Espina, Lance A. Liotta

^*Corresponding author for this work

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

Abstract

Reverse phase protein microarray(s) (RPMA) is a proteomic technology that can generate a quantitative, precise, and highly sensitive profile of hundreds of protein and phosphoprotein endpoints from a very small input of tissue or cells. Herein we review the history of RPMA creation and development and show how this special platform has graduated from the research lab to the clinical trial arena. RPMA technology is now being used to gather data from human clinical core needle specimens before and after molecular-targeted therapy. RPMA is also being used in combination with genomic analysis for the individualized selection of therapy for stage IV breast cancer. RPMA technology generates data that can be used to visualize activated protein pathways and functional interconnections both inside and outside a cell. This information will be critical to realize the goal of individualized therapy tailored to the functional molecular network of the diseased cells.

Original language	English
Title of host publication	Proteomic and Metabolomic Approaches to Biomarker Discovery
Publisher	Elsevier Inc.
Pages	349-361
Number of pages	13
ISBN (Print)	9780123944467
DOIs	https://doi.org/10.1016/B978-0-12-394446-7.00022-4
State	Published - Jun 2013
Externally published	Yes

Keywords

Cancer
Individualized therapy
Kinase pathways
Protein arrays
Reverse phase
Signal transduction

Access to Document

10.1016/B978-0-12-394446-7.00022-4

Cite this

@inbook{d088cd9083a847428156a3981a4f7c89,

title = "Reverse Phase Protein Microarray Technology: Advances into the Clinical Research Arena",

abstract = "Reverse phase protein microarray(s) (RPMA) is a proteomic technology that can generate a quantitative, precise, and highly sensitive profile of hundreds of protein and phosphoprotein endpoints from a very small input of tissue or cells. Herein we review the history of RPMA creation and development and show how this special platform has graduated from the research lab to the clinical trial arena. RPMA technology is now being used to gather data from human clinical core needle specimens before and after molecular-targeted therapy. RPMA is also being used in combination with genomic analysis for the individualized selection of therapy for stage IV breast cancer. RPMA technology generates data that can be used to visualize activated protein pathways and functional interconnections both inside and outside a cell. This information will be critical to realize the goal of individualized therapy tailored to the functional molecular network of the diseased cells.",

keywords = "Cancer, Individualized therapy, Kinase pathways, Protein arrays, Reverse phase, Signal transduction",

author = "Petricoin, {Emanuel F.} and Brian Leyland-Jones and Julie Wulfkuhle and Marielena Pierobon and Claudius Mueller and Virginia Espina and Liotta, {Lance A.}",

note = "Funding Information: The purpose of this trial, sponsored by TGen Drug Development Services and funded through the SIDE-OUT Foundation, is to employ molecular profiling to individualize therapy for patients with refractory, metastatic breast cancer ( Table 1 ). In order to assess whether individualized therapy can change the clinical course of disease, a growth modulation index (GMI) will be calculated for each patient. The GMI is calculated as the ratio of progression-free survival (PFS) under the individualized therapy to the time to progression (TTP) for the most recent regimen on which the patient has progressed. ",

year = "2013",

month = jun,

doi = "10.1016/B978-0-12-394446-7.00022-4",

language = "English",

isbn = "9780123944467",

pages = "349--361",

booktitle = "Proteomic and Metabolomic Approaches to Biomarker Discovery",

publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - Reverse Phase Protein Microarray Technology

T2 - Advances into the Clinical Research Arena

AU - Petricoin, Emanuel F.

AU - Leyland-Jones, Brian

AU - Wulfkuhle, Julie

AU - Pierobon, Marielena

AU - Mueller, Claudius

AU - Espina, Virginia

AU - Liotta, Lance A.

N1 - Funding Information: The purpose of this trial, sponsored by TGen Drug Development Services and funded through the SIDE-OUT Foundation, is to employ molecular profiling to individualize therapy for patients with refractory, metastatic breast cancer ( Table 1 ). In order to assess whether individualized therapy can change the clinical course of disease, a growth modulation index (GMI) will be calculated for each patient. The GMI is calculated as the ratio of progression-free survival (PFS) under the individualized therapy to the time to progression (TTP) for the most recent regimen on which the patient has progressed.

PY - 2013/6

Y1 - 2013/6

N2 - Reverse phase protein microarray(s) (RPMA) is a proteomic technology that can generate a quantitative, precise, and highly sensitive profile of hundreds of protein and phosphoprotein endpoints from a very small input of tissue or cells. Herein we review the history of RPMA creation and development and show how this special platform has graduated from the research lab to the clinical trial arena. RPMA technology is now being used to gather data from human clinical core needle specimens before and after molecular-targeted therapy. RPMA is also being used in combination with genomic analysis for the individualized selection of therapy for stage IV breast cancer. RPMA technology generates data that can be used to visualize activated protein pathways and functional interconnections both inside and outside a cell. This information will be critical to realize the goal of individualized therapy tailored to the functional molecular network of the diseased cells.

AB - Reverse phase protein microarray(s) (RPMA) is a proteomic technology that can generate a quantitative, precise, and highly sensitive profile of hundreds of protein and phosphoprotein endpoints from a very small input of tissue or cells. Herein we review the history of RPMA creation and development and show how this special platform has graduated from the research lab to the clinical trial arena. RPMA technology is now being used to gather data from human clinical core needle specimens before and after molecular-targeted therapy. RPMA is also being used in combination with genomic analysis for the individualized selection of therapy for stage IV breast cancer. RPMA technology generates data that can be used to visualize activated protein pathways and functional interconnections both inside and outside a cell. This information will be critical to realize the goal of individualized therapy tailored to the functional molecular network of the diseased cells.

KW - Cancer

KW - Individualized therapy

KW - Kinase pathways

KW - Protein arrays

KW - Reverse phase

KW - Signal transduction

UR - http://www.scopus.com/inward/record.url?scp=84902036903&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-394446-7.00022-4

DO - 10.1016/B978-0-12-394446-7.00022-4

M3 - Chapter

AN - SCOPUS:84902036903

SN - 9780123944467

SP - 349

EP - 361

BT - Proteomic and Metabolomic Approaches to Biomarker Discovery

PB - Elsevier Inc.

ER -

Reverse Phase Protein Microarray Technology: Advances into the Clinical Research Arena

Abstract

Keywords

Access to Document

Fingerprint

Cite this